The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1276
December 17, 2007
View Complete Issue         Table of Contents 2019 
Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma
December 17, 2007 (Issue: 1276)
Temsirolimus (Torisel - Wyeth), an mTOR (mammalian target of rapamycin) kinase inhibitor that is metabolized to sirolimus (rapamycin), has been approved by the FDA for intravenous treatment of advanced renal cell carcinoma.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Temsirolimus (Torisel) for Advanced Renal Cell Carcinoma
Article code: 1276c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.